Patents Examined by W. Gary Jones
  • Patent number: 6573054
    Abstract: The present invention relates to a method for detecting the amount of a target polynucleotide in a sample. A combination is provided in a medium. The combination comprises (i) a sample suspected of containing the target polynucleotide, the target polynucleotide being in single stranded form, (ii) a reference polynucleotide comprising a sequence that is common with a sequence of the target polynucleotide, and (iii) a predetermined amount of an oligonucleotide probe that has a sequence that hybridizes with the sequence that is common. The combination is subjected to conditions for amplifying the target polynucleotide and the reference polynucleotide. The conditions permit formation of substantially non-dissociative complexes of the target polynucleotide and the reference polynucleotide, respectively, with the oligonucleotide probe. Furthermore, the predetermined amount of the oligonucleotide probe is less than the expected amount of the amplified target polynucleotide.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: June 3, 2003
    Assignee: Dade Behring Inc.
    Inventors: Rajesh Patel, Nurith Kurn
  • Patent number: 6566061
    Abstract: Nucleic acid sequences within the q13 region of the X chromosome having polymorphisms associated with neuropsychiatric disorders and associated conditions are disclosed herein. One polymorphism occurs within the coding region of the HOPA gene and introduces a four amino acid insertion into a putative OPA domain, a domain which has been shown to be involved in tissue specific expression. Compositions including nucleic acids having these polymorphisms and antibodies to polymorphic regions within proteins encoded in the PCTG4 region are provided. Methods of using the information and nucleic acid sequences disclosed herein for the diagnosis and assessment of pathologies associated with neuropsychiatric disorders and associated conditions are also provided.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: May 20, 2003
    Assignees: The University of Iowa, as represented by the University of Iowa Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert A. Philibert, Edward I. Ginns, Lynn Delisi
  • Patent number: 6566056
    Abstract: Yeast strains carrying a human wild-type TP53 are employed to select for mutations. The types of mutations can be analyzed genetically as recessive or dominant-negative. The mutational spectrum of dominant-negative TP53 mutants selected in yeast correlates tightly with TP53 mutations found in human cancers. Thus the use of such yeast assays is validated for studying the effects of various agents on human TP53, one of the most important and ubiquitous of human cancer genes. Assays, kits, and constructs are provide which use yeast as a genetic system for making and studying human TP53 mutations. Such assays can be used to develop therapeutic agents, to study putative carcinogens, and to identify other cellular components which interact with p53 and abrogate its activity.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: May 20, 2003
    Assignee: The Johns Hopkins University
    Inventors: Jef D. Boeke, Rainer K. Brachmann
  • Patent number: 6566102
    Abstract: Compositions, methods and diagnostic devices for monitoring graft integrity in xenotransplantation and for detecting infectious agents transmitted by the xenograft are described. In particular, the compositions, methods and devices are useful for determining porcine xenograft integrity and persistence and can detect the presence of PERV (porcine endogenous retrovirus) in a biological sample. The compositions, methods and devices are useful for determining or monitoring graft survival and rejection in recipients of xenografts and are useful for detecting the presence of pig cell and PERV infection in a xenotransplant recipient or donor. In addition, the compositions, methods and devices are useful for screening therapeutic products to be administered to humans to ensure that the products are free of pig cells, and thus free of PERV contamination, prior to administration.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: May 20, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: William M. Switzer, Walid Heneine, Shanmugam Vedapuri
  • Patent number: 6562563
    Abstract: Compositions and methods are provided for identifying agents that alter mitochondrial membrane permeability transition. The screening methods generally detect agents that alter the interaction between the mitochondrial adenine nucleotide translocator and cyclophilin D. Such agents may be used, for example, in the treatment of a variety of conditions associated with altered mitochondrial function.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: May 13, 2003
    Assignee: Mitokor
    Inventors: Anne N. Murphy, William Clevenger, Sandra Eileen Wiley, Alexander Y. Andreyev, Luciano G. Frigeri, Gonul Velecelebi, Robert E. Davis
  • Patent number: 6562566
    Abstract: The present invention relates to a method of sequencing DNA by oligomer hybridization, DNA/RNA hybrid oligomers applied onto a support and optionally DNA oligomers and/or RNA oligomers being used as hybridization matrix.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: May 13, 2003
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventor: Jörg Hoheisel
  • Patent number: 6562573
    Abstract: This invention describes materials and methods usable for the purification of polyelectrolytes, such as nucleic acids and proteins. The materials of the invention are separation media that possess pH-dependent groups with pKa value in the range of about 5 to about 7. Separation of the nucleic acids or proteins from a separation medium is effected at a neutral or higher pH.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: May 13, 2003
    Inventor: Folim G. Halaka
  • Patent number: 6559296
    Abstract: The present invention relates to an apparatus for detecting nucleic acid molecules such as target DNA molecules and mRNA molecules by using a DNA probe, and provides a DNA capillary, comprising a fluid passageway formed of a cylindrical capillary made of glass, a plurality of independent probe regions formed in the inner wall of the fluid passageway, and DNA probes each immobilized in the probe region, the immobilized DNA probes differing from each other. For performing the measurement, a sample is introduced through an open portion into the capillary so as to perform reaction and, then, fluorimetry.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: May 6, 2003
    Assignee: Olympus Optical Co., Ltd.
    Inventor: Akira Suyama
  • Patent number: 6558905
    Abstract: Diagnostics and therapeutics for osteoporosis, which are based on the identification of the subject's IL-1 haplotype pattern are described.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: May 6, 2003
    Assignee: Interleukin Genetics, Inc.
    Inventors: Simon van Dijk, Gordon W. Duff
  • Patent number: 6558901
    Abstract: The present invention relates to the detection of specific nucleic acid sequences, either by a process of amplification of specific nucleic acid sequences or not. More particularly the invention provides for improved compositions and methods for reducing the chance for contamination from manipulation of reagents, internal controls for amplification, and the use of automated apparatus for the automated detection of one, or more than one amplified nucleic acid sequences.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: May 6, 2003
    Assignee: bioMerieux Vitek
    Inventors: Luigi Catanzariti, Bryan W. Kluttz, Marcela Vera-Garcia, J. Lawrence Burg, James G. Moe, Geoff A. McKinley
  • Patent number: 6555734
    Abstract: The invention includes modified dihydroflavonol 4-reductase (DFR) nucleic acids encoding the modified DFR that has altered amino acid sequences at the substrate specificity determining region. The property of the modified DFR is characterized by its ability to reduce dihydrokaempferol (DHK) preferentially over dihydroquercetin (DHQ), and dihydromyricetin (DHM). The invention also includes plants having at least one cell expressing the modified DFR. Such plants are characterized by the increased content of pelargonidin-based pigments. The invention also includes vectors comprising at least a portion of the modified DFR nucleic acids. The invention also includes methods using such vectors for producing plants having the increased content of pelargonidin-based pigments.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: April 29, 2003
    Assignee: Korea Kumho Petrochemical Co., Ltd.
    Inventors: Giltsu Choi, Eric I. Johnson, Hankuil Yi, Byongchul Shin
  • Patent number: 6555654
    Abstract: A novel receptor, “LDL-receptor related protein-3” (“LRP-3”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: April 29, 2003
    Assignee: The Wellcome Trust Limited as Trustee for the Wellcome Trust
    Inventors: John A. Todd, John W. Hess, Charles T. Caskey, Roger D Cox, David Gerhold, Holly Hammond, Patricia Hey, Yoshihiko Kawaguchi, Tony R. Merriman, Michael L. Metzker, Yusuke Nakagawa, Michael S. Phillips, Rebecca C. J. Twells
  • Patent number: 6555666
    Abstract: Substantially-isolated polynucleotides encoding human polypeptides having immunomodulatory activity; human homologs of yeast RAD50, Drosophila Septin-2 and rat Acyl-CoA Synthetase compositions and methods; method for detecting the presence of activated T-cells.
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: April 29, 2003
    Inventor: Gregory Dolganov
  • Patent number: 6551812
    Abstract: The present invention describes polynucleotides and polypeptides associated with PPAR&agr;-mediated pathways that are useful as therapeutic compositions in method for the treatment of peroxisomal disorders. These polynucleotides and polypeptides were identified through the use of differentioal gene expression analysis. In particular, the present invention discloses eleven novel gene fragments, and numerous single nucleotide polymorphisms, located in previously disclosed genes, all of which have been discovered to be associated with PPAR&agr;-mediated pathways.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: April 22, 2003
    Assignee: CuraGen Corporation
    Inventor: Bonnie Gould-Rothberg
  • Patent number: 6551776
    Abstract: The invention concerns an oligonucleotide capable of being specifically hybridized with the ribosomal RNA (RNAr) or with the corresponding gene (ADNr) of the Escherichia coli genomic species (including all the Shigella genomic species except for serotype 13 S. boydii/Escherichia fergusonii genomic species. The invention also concerns a method for detecting and displaying the bacteria of said species.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: April 22, 2003
    Assignee: Institut Pasteur
    Inventors: Patrick Grimont, Béatrice Regnault, Monique Collin
  • Patent number: 6551780
    Abstract: The present invention provides for methods of typing a melanocytic neoplasm, in particular for classifying a Spitz nevus. The methods comprise detecting in a tumor sample the presence of an increase in copy number of the whole chromosome 11p arm, particularly the presence of an 11p isochromosome, which is associated with the presence of a Spitz nevus. The invention further provides methods of typing a melanocytic neoplasm by detecting the presence of a mutated H-RAS gene, which is also associated with the presence of a Spitz nevus.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: April 22, 2003
    Assignee: The Regents of University of California
    Inventors: Boris Bastian, Daniel Pinkel
  • Patent number: 6548651
    Abstract: The present invention relates to novel drugs which may be used in combating infectious micro-organisms, particularly bacteria. More specifically, the invention relates to peptide nucleic acid (PNA) sequences that are modified by conjugating cationic peptides to the PNA moiety in order to obtain novel PNA molecules that exhibit enhanced anti-infective properties.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: April 15, 2003
    Assignees: Pantheco A/S
    Inventors: Peter E. Nielsen, Liam Good, Henrik Frydenlund Hansen, Frederik Beck, Leila Malik, Carsten Schou, Margit Wissenbach, Birgit Kjaeldgaard Giwercman
  • Patent number: 6548650
    Abstract: This invention provides a method for producing a temporally paced subtracted cDNA library comprising: a) isolating temporally spaced RNAs from cells; b) generating cDNA inserts from the RNAs isolated from step (a); c) producing a temporally spaced cDNA library having clones containing the cDNA inserts generated from step (b); d) producing double stranded cDNA inserts from the temporally spaced cDNA library; e) denaturing the double stranded cDNA inserts; f)contacting the denatured double stranded cDNA inserts produced in step (e) with single-stranded DNAs from another cDNA library under conditions permitting hybridization of the single-stranded DNAs and the double-stranded cDNA inserts; g) separating the hybridized cDNA inserts from the unhybridized inserts; h) generating a cDNA library of the unhybridized inserts, thereby generating a temporally spaced subtracted cDNA library.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: April 15, 2003
    Assignee: Trustees of Columbia University in the City of New York
    Inventor: Paul B. Fisher
  • Patent number: 6548250
    Abstract: The invention relates to a method of generating a signal indicative of the presence of a target nucleic acid sequence in a sample, where the method includes forming a cleavage structure by incubating a sample containing a target nucleic acid sequence with a nucleic acid polymerase and cleaving the cleavage structure with a FEN nuclease to generate a cleaved nucleic acid fragment. The invention also relates to methods of detecting or measuring a target nucleic acid sequence, where the method includes forming a cleavage structure by incubating a target nucleic acid sequence with a nucleic acid polymerase, cleaving the cleavage structure with a FEN nuclease and detecting or measuring the release of a fragment.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: April 15, 2003
    Assignee: Stratagene
    Inventor: Joseph A. Sorge
  • Patent number: 6548259
    Abstract: The invention relates to a set of combinatorially labeled oligonucleotide probes each member thereof: (i) having a predetermined label distinguishable from the label of any other member of said set, and (ii) being capable of specifically hybridizing with a predetermined chromosome or nucleic acid molecule, and to the use of such molecules, alone or in concert with nucleic acid amplification methods.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: April 15, 2003
    Assignee: Yale University
    Inventors: David C. Ward, Michael Speicher, Stephen Gwyn Ballard, John T. Wilson